

Lack of association between use of efavirenz and death from suicide: the D:A:D Study

Colette Smith, Lene Ryom, Antonella d'Arminio Monforte,
Peter Reiss, Amanda Mocroft, Wafaa el Sadr, Rainer Weber,
Mathew Law, Caroline Sabin, Jens Lundgren

On behalf of the D:A:D Study Group

D:A:D

Background

- A recent meta-analysis found a 2.28-fold increased rate of suicidality events among HIV-positive people receiving EFV compared to other, predominantly PI-based, regimens*
- There was an almost 3-fold higher rate of completed/attempted suicides, but number of events was small (22 events)
- We investigated whether the association between use of EFV and death from suicide observed in the clinical trial setting was replicated in an large observational study

* Mollan et al. Ann Intern Med 2014. 161(1): 1-10

Methods 1

- Participants were from the Data collection on Adverse events of anti-HIV Drugs (D:A:D) Study, a collaboration of 11 cohort studies in Europe, USA, and Australia
- Consistent classification categories for causes of death was used across the study period following Coding of Causes of Death (CoDe) methodology*
- Individuals were followed from D:A:D entry to the first of death, 6 months after last clinic visit or 1st February 2013
- Incidence rate ratios calculated using Poisson regression

* Kowalska et al. Epidemiology 2011. 22(4): 516-23


Methods 2

- CoDe methodology allows for multiple causes of death to be listed:
 - 1 underlying cause
 - 1 immediate cause
 - Up to 4 contributory causes
- The primary outcome was defined in two ways as:
 - Suicide or psychiatric disease listed as underlying cause of death
 - Suicide or psychiatric disease listed as any of the underlying, immediate or contributing causes of death
- Exposure: current ART use


Characteristics at study entry

		Number (n=49717)	%
Gender	Male	36664	74
Risk	MSM	21922	44
	IDU	7619	15
	Heterosexual	16202	33
	Other/Unknown	3974	8
Ethnicity	White	25171	51
	Black	4872	10
	Other/Unknown	19674	40
Previous AIDS	Yes	10491	21
Viral load<400 c/ml	Yes	20968/47423	44
CD4 (cells/ μ L)	Median (IQR)	400	243, 590
Age (years)	Median (IQR)	38	32, 45
Any ART	N	30383	61
Total years	Median (IQR)	2.9	1.2, 4.8

Death Rates (person-years=371,333)



Death Rates according to ART regimen



Association between ART regimen and suicide/psychiatric disease

	Unadjusted	
	IRR	95% CI
Suicide or Psychiatric disease (underlying cause)		
EFV-containing	0.59	0.33, 1.06
Other NNRTI-containing	0.93	0.53, 1.62
Other ART	0.81	0.49, 1.32
No ART – naïve	1.00	-
No ART – experienced	3.24	1.95, 5.38

*Adjusted for nadir CD4 count, current CD4 count, age, gender, time since HIV diagnosis, cohort, previous clinical event and risk for HIV acquisition. All $p < 0.0001$

Association between ART regimen and suicide/psychiatric disease

	Unadjusted		Adjusted	
	IRR	95% CI	IRR	95% CI
Suicide or Psychiatric disease (underlying cause)				
EFV-containing	0.59	0.33, 1.06	0.56	0.29, 1.07
Other NNRTI-containing	0.93	0.53, 1.62	0.94	0.50, 1.77
Other ART	0.81	0.49, 1.32	0.76	0.43, 1.36
No ART – naïve	1.00	-	1.00	-
No ART – experienced	3.24	1.95, 5.38	3.38	1.91, 5.97

*Adjusted for nadir CD4 count, current CD4 count, age, gender, time since HIV diagnosis, cohort, previous clinical event and risk for HIV acquisition. All p<0.0001

Association between ART regimen and suicide/psychiatric disease

	Unadjusted		Adjusted	
	IRR	95% CI	IRR	95% CI
Suicide or Psychiatric disease (underlying cause)				
EFV-containing	0.59	0.33, 1.06	0.56	0.29, 1.07
Other NNRTI-containing	0.93	0.53, 1.62	0.94	0.50, 1.77
Other ART	0.81	0.49, 1.32	0.76	0.43, 1.36
No ART – naïve	1.00	-	1.00	-
No ART – experienced	3.24	1.95, 5.38	3.38	1.91, 5.97
Suicide or Psychiatric disease (underlying, immediate or contributory cause)				
EFV-containing	0.50	0.35, 0.71	0.42	0.28, 0.63
Other NNRTI-containing	0.73	0.52, 1.03	0.68	0.46, 1.00
Other ART	0.67	0.50, 0.90	0.52	0.37, 0.73
No ART – naïve	1.00	-	1.00	-
No ART – experienced	2.71	2.00, 3.67	2.29	1.63, 3.21

*Adjusted for nadir CD4 count, current CD4 count, age, gender, time since HIV diagnosis, cohort, previous clinical event and risk for HIV acquisition. All p<0.0001

Characteristics at time of suicide

		EFV-based ART	Other ART	No ART – naïve	No ART – experienced
N (%)		60	234	62	126
Gender	Male	49 (82)	201 (86)	48 (77)	104 (83)
Risk	IDU	31 (52)	74 (32)	32 (52)	51 (40)
Age (years)	Median [IQR]	44 [36-48]	44 [39-52]	37 [29-43]	44 [38-50]
VL<400 c/ml	Yes	32 (53)	140 (60)	1 (2)	44 (35)
CD4 (cells/ μ L)	Median [IQR]	350 [179-561]	407 [230-630]	501 [377-642]	338 [174-509]
Last ART regimen	EFV-based Other NNRTI Other	-	-	-	29 (23) 19 (15) 78 (62)
Time since last ART (years)	<0.5 0.5-1 1-2 2+	-	-	-	77 (61) 19 (15) 10 (8) 20 (16)

Other predictors

- Death from suicide/psychiatric disease was more common for:
 - Lower current CD4 count
 - Men
 - Older age
 - IDU risk for HIV transmission

Sensitivity analyses

- Re-defining outcome as:
 - Suicide (without psychiatric disease) listed as underlying cause of death
 - Any of: suicide; psychiatric disease; accident or other violent death; substance abuse; chronic alcohol abuse; chronic IVDU; CNS disease; acute intoxication as underlying, immediate or contributing cause
- Consider ART regimen received with 3- and 6-month time-lag
- Analyses stratified by mode of HIV acquisition
- Analyses restricted to those ART-naïve at baseline

Conclusions

- Amongst those in routine clinical care, observed rates of death from suicide/related causes for those receiving EFV-based ART similar to those for other regimens
- ART choices at clinician's and patient's discretion, and so likely that ART groups not comparable with respect to presence of underlying psychiatric and CNS-related disorders
- Findings do not rule out possibility EFV leads to increased risk of suicide, but do provide re-assurance that the way EFV is used is not leading to increased suicide rates for those on the drug

Acknowledgements

Steering Committee: Members indicated w/ *; ¢ chair;

Cohort PIs: W El-Sadr* (CPCRA), G Calvo* (BASS), F Dabis* (Aquitaine), O Kirk* (EuroSIDA), M Law* (AHOD), A d'Arminio Monforte* (ICONA), L Morfeldt* (HivBIVUS), C Pradier* (Nice), P Reiss* (ATHENA), R Weber* (SHCS), S De Wit* (Brussels)

Cohort coordinators and data managers: M Hillebreght, S Zaheri, L Gras, (ATHENA), M Bruyand, S Geffard, E Pernot, J Mourali (Aquitaine), H McManus, S Wright (AHOD), S Mateu, F Torres (BASS), M Delforge (Brussels), G Bartsch, G Thompson (CPCRA), J Kjær, Dennis Kristensen (EuroSIDA), I Fanti (ICONA), E Fontas, C Caissotti (Nice), A Sundström, G Thulin (HivBIVUS), M Rickenbach (SHCS)

Statisticians: CA Sabin*, AN Phillips*, DA Kamara, CJ Smith, A Mocroft

D:A:D coordinating office: L Ryom, CI Hatleberg, RS Brandt, D Raben, C Matthews, A Bojesen, J Nielsen, JD Lundgren*¢

Member of the D:A:D Oversight Committee: B Powderly*, N Shortman*, C Moecklinghoff *, G Reilly*, X Franquet*

D:A:D working group experts: Kidney: L Ryom, A Mocroft, O Kirk *, P Reiss *, M Ross, CA Fux, P Morlat, O Moranne, AM Kesselring, DA Kamara, CJ Smith, JD Lundgren *¢

Mortality: CJ Smith, L Ryom, AN Phillips *, R Weber*, P Morlat, C Pradier *, P Reiss *, N Friis-Møller, J Kowalska, JD Lundgren*¢ **Cancer:** CA Sabin *, L Ryom, M Law *, A d'Arminio Monforte*, F Dabis*, M Bruyand, P Reiss *, CJ Smith, DA Kamara, M Bower, G Fätkenheuer, A Donald, A Grulich, JD Lundgren*¢

External endpoint reviewer: A Sjøøl (CVD), P Meidahl (oncology), JS Iversen (nephrology)

Funding: 'Oversight Committee for The Evaluation of Metabolic Complications of HAART' with representatives from academia, patient community, FDA, EMA and a consortium of AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, ViiV Healthcare, Merck, Pfizer, F. Hoffmann-La Roche and Janssen Pharmaceuticals